T his issue of Circulation Research includes 3 interesting studies that represent new concepts of AT 1 receptor-mediated cell signaling in the cardiovascular system, which is currently of intense interest. The AT 1 receptor mediates many important cardiovascular responses, including vasoconstriction, vascular and cardiac remodeling (cell proliferation, hypertrophy, and production of extracellular matrix), and cell survival/cell death. The AT 1 receptor belongs to the seven membrane-spanning GPCR family and typically activates PLC␤ through the heterotrimeric G q protein, causing production of inositol trisphosphate and diacylglycerol. Besides this classical GPCR-G q -PLC␤ pathway, recent studies indicate that Ang II activates both nonreceptor-type and receptor-type tyrosine kinases, which are typically activated by cytokine and EGFR stimulation. Activation of tyrosine kinases by Ang II is of great interest for a variety of reasons. First, tyrosine kinase-dependent signaling pathways mediate major growth effects of Ang II in cardiovascular systems.
T his issue of Circulation Research includes 3 interesting studies that represent new concepts of AT 1 receptor-mediated cell signaling in the cardiovascular system, which is currently of intense interest. The AT 1 receptor mediates many important cardiovascular responses, including vasoconstriction, vascular and cardiac remodeling (cell proliferation, hypertrophy, and production of extracellular matrix), and cell survival/cell death. The AT 1 receptor belongs to the seven membrane-spanning GPCR family and typically activates PLC␤ through the heterotrimeric G q protein, causing production of inositol trisphosphate and diacylglycerol. Besides this classical GPCR-G q -PLC␤ pathway, recent studies indicate that Ang II activates both nonreceptor-type and receptor-type tyrosine kinases, which are typically activated by cytokine and EGFR stimulation. Activation of tyrosine kinases by Ang II is of great interest for a variety of reasons. First, tyrosine kinase-dependent signaling pathways mediate major growth effects of Ang II in cardiovascular systems. 1 Sayeski et al 2 reports that a 130-kDa protein, which is tyrosine-phosphorylated by Ang II, is identified as p130 Cas and that it potentially works as an effector of Src and PKC in VSMCs. Second, since the AT 1 receptor possesses neither intrinsic protein tyrosine kinase activities nor known physical association with tyrosine kinases except interaction with JAK2, 3 the linkage between the AT 1 receptor and the tyrosine kinases was unexpected. Murasawa et al 4 reports that Ang II transactivates the EGFR, which in turn mediates DNA synthesis in cardiac fibroblasts. Third, tyrosine kinases mediate activation of small GTP binding proteins (the Ras and Rho family) and downstream MAP kinases. Schmitz et al 5 reports that Ang II activates the ␣PAK-JNK pathway via a tyrosine kinase-dependent mechanism in VSMCs. Since a comprehensive review on tyrosine kinase activation by Ang II has appeared recently, 1, 6 the focus of this editorial is to highlight findings of the most recent literature, including both cardiovascular and noncardiovascular systems, and the future direction of those new concepts regarding AT 1 receptor cell signaling.
Nonreceptor-Type Tyrosine Kinases
Since several groups have reported that Ang II increases the phosphotyrosine content of cellular proteins in liver GN4 cells, VSMCs, and cardiac myocytes/fibroblasts, many of these phosphotyrosine-containing proteins and the tyrosine kinases, which are responsible for the tyrosine phosphorylation, have been identified (reviewed in Reference 1). The phosphotyrosine-containing proteins identified thus far include protein kinases/phosphatases (Jak2, Tyk2, FAK, PYK2, Src, ERK, and PTP-1D), enzymes/regulatory proteins (PLC-␥1 and IRS-1), adapter proteins (Shc and paxillin), and transcription factors (Stat1, Stat3, and Stat5). 6 Sayeski et al 2 found that another protein, p130 Cas , is tyrosine-phosphorylated by Ang II in VSMCs. It has been recently shown that p130
Cas mediates FAK-promoted cell migration on fibronectin in CHO-K1 cells. 7 Interestingly, p130
Cas physically interacts not only with Src and pp120 but also with PKC␣ in VSMCs. Sayeski et al have proposed that p130
Cas works as a docking site, which attracts molecules associated with the 3 separate important signaling pathways (namely, Src, PKC, and focal adhesion-related signaling pathways) into one place. The physical interaction between p130
Cas and these individual signaling molecules apparently takes place with different kinetics. These spatial and temporal regulations of protein-protein interactions will allow the AT 1 receptor to control cellular events with more precision.
Ang II activates Src-family tyrosine kinases in cardiac myocytes and VSMCs. 8, 9 Activation of Src-family tyrosine kinases by Ang II mediates tyrosine phosphorylation of many proteins, including phospholipase C␥1, Shc, p97, pp120, and p130
Cas , and activation of the downstream signaling molecules, such as Ras and ERKs. 10 The mechanism of Src activation by AT 1 receptor stimulation has not been fully elucidated. In VSMCs, activation of PLC and the subsequent production of inositol trisphosphate and diacylglycerol depend on Src, since PLC-␥1 is the predominant isoform of PLC in this cell type. 11 Tyrosine kinase may control the function of heterotrimeric G q protein, since tyrosine phosphorylation of the C-terminal end amino acid sequence in G q ␣ has been shown to be essential for the function of G q ␣.
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These results raise an interesting question: Is Src activated by a mechanism independent of (or rather upstream from) the G q -PLC␤ pathway? The definitive answer to this question does not seem to have been obtained as of yet. Although JAK2 is activated by Ang II through direct association with the C-terminal cytoplasmic domain of the AT 1 receptor, such direct association between Src and the AT 1 receptor is unlikely. 8 Multiple mechanisms have been hypothesized for Src activation by other growth factors. These include involvement of receptor-type or nonreceptor-type tyrosine kinases, 13 tyrosine phosphatases, 14 the G ␤␥ subunit, 15 and high-affinity SH2/SH3 domain-containing proteins.
14 It remains to be seen whether or not these molecules contribute to Ang II-induced Src activation.
Besides Src, FAK and PYK2 (also known as Ca 2ϩ -dependent tyrosine kinase) are also activated by Ang II. 16 The mechanism of activation, time course of activation, subcellular localization, and substrate specificity all seem different among these tyrosine kinases.
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Receptor-Type Tyrosine Kinases
Murasawa et al 4 have reported that Ang II transactivates the EGFR tyrosine kinase, which in turn mediates Ang IIinduced mitogenic responses in cardiac fibroblasts. Transactivation of the EGFR tyrosine kinase by GPCR was originally reported in Rat-1 fibroblasts stimulated with endothelin-1, thrombin, or lysophosphatidic acid. 18 Since then, similar observations have been reported, and transactivation of the EGFR family is likely to be a common and important mechanism for the GPCR to use the cell tyrosine kinasesignaling machinery. This apparently ligand-independent activation of the receptor type tyrosine kinase is also observed when cells are stimulated with ultraviolet irradiation, growth hormone, and cytokines. 19 Murasawa et al have shown that selective inhibition of the EGFR tyrosine kinase activity by AG1478 and the dominant-negative EGFR mutant inhibits Ang II-induced transactivation of the EGFR. Thus, both tyrosine kinase activities and dimerization of the EGFR seem to be required. The EGFR seems to be autophosphorylated in response to Ang II as if it were activated by EGF binding. Murasawa et al excluded the possibility that Ang II causes autocrine secretion of EGF, implying an alternative mechanism of ligand-independent EGFR activation. Studies of GPCR-induced EGFR activation in COS-7 cells and GN4 liver cells indicate that Src-family tyrosine kinases, FAK and PYK2, are unlikely to mediate this response. 20 In cardiac fibroblasts and VSMCs, Ca 2ϩ calmodulin inhibitors and Ca 2ϩ chelators abolish Ang II-induced transactivation of the EGFR. 4, 21 In GN4 rat liver cells, Ang II-induced transactivation of the EGFR is suppressed by PKC. 20 A possible mechanism explaining these observations may be the involvement of unknown (Ca 2ϩ -dependent and/or PKC-sensitive) tyrosine kinases or phosphatases, whose activation or inhibition, respectively, could account for the GPCR-mediated EGFR-tyrosine phosphorylation. In any case, these intermediate molecules, either tyrosine kinases or phosphatases, are likely to have a substrate specificity toward the EGFR over other receptor-type tyrosine kinases, since EGFR is most preferentially transactivated by Ang II. Alternatively, Ang II may stimulate dimer formation of a phosphotyrosinecontaining protein that interacts with the EGFR. A similar mechanism has been recently shown for interleukin-6 -induced ErbB2 receptor tyrosine kinase activation, where activated gp130 receptor dimers recruit ErbB2 receptor tyrosine kinase to the complex, leading to ErbB2 clustering and kinase activation. 19 Availability of the receptor tyrosine kinase pathway depends on the existence of the appropriate receptor tyrosine kinase and intermediate molecules. For example, neonatal and adult cardiac myocytes respond poorly to EGF stimulation, 22 suggesting that the EGF pathway may not be a major Ang II-regulated tyrosine kinase pathway in these preparations.
Ras-and Rho-Family Small GTP Binding Proteins and Downstream MAP Kinases
Small GTP binding proteins, such as those in the Ras and Rho families, are activated by ligands for the tyrosine kinase receptors, the cytokine receptors, and the GPCRs. A growing number of molecules have been identified as effector molecules for each small GTP binding protein (reviewed in Reference 23 16 It has been suggested that tyrophostin-sensitive (unidentified) tyrosine kinases mediate activation of Rho by GPCRs. 26 Although Ras is constitutively in the cell membrane, Rho and Rac are predominantly cytosolic and must translocate to the cell membrane to be activated. 23 Therefore, the distinct subcellular localization seems to be well correlated with the hypothesis that the Ras and Rho families may be regulated by distinct tyrosine kinases.
Direct Association of Signaling Molecules
With the AT 1 Receptor
The AT 1 receptor has been shown to directly associate with intracellular signaling molecules, such as Jak2, PTP-1D, and PLC-␥1. This ligand-dependent interaction requires a YIPP motif in the C-terminal domain of the AT 1 receptor. 27, 28 The
Selected Abbreviations and Acronyms
Ang II ϭ angiotensin II AT 1 ϭ Ang II type 1 EGF ϭ epidermal growth factor EGFR ϭ EGF receptor ERK ϭ extracellular signal-regulated kinase GPCR ϭ G protein-coupled receptor JAK ϭ Janus kinase JNK ϭ c-Jun N-terminal kinase MAP kinase ϭ mitogen-activated protein kinase PAK kinase ϭ p21-activated kinase PKC ϭ protein kinase C PLC␤ ϭ phospholipase C␤ VSMC ϭ vascular smooth muscle cell interaction between the AT 1 receptor and intracellular signaling molecules creates membrane-delimited signal transduction complexes similar to those observed for receptor type tyrosine kinases. The AT 1 receptor associates with a Stat5 transcription factor after Ang II stimulation and apparently forms complexes with JAK2. The putative Stat5 binding motif (YXXL) has been found on intracellular loop 1 and on the carboxyl tail of the AT 1 receptor. 29 Small GTP binding proteins, ARF and RhoA, have been shown to interact with the amino acid sequence containing NPXXY (amino acids 298 to 302) in the seventh transmembrane domain of the AT 1 receptor in an Ang II-dependent manner in rat anterior pituitary cells. This direct interaction between the GPCR and ARF/RhoA seems to enhance coupling between the GPCR and phospholipase D. 30 Interestingly, the NPXXY motif is not found in all Gq-coupled receptors. Conversion of the DPXXY motif in another Gq-coupled gonadotropin-releasing hormone receptor to the NPXXY motif confers sensitivity to an inhibitor of ARF, suggesting that GPCRs utilize the sequence-specific cell signaling. 30 A similar direct interaction between GPCRs and the signaling molecule has been recently reported in the case of ␤-adrenergic receptor and the Na ϩ /H ϩ exchanger. 31 The functional role of the direct interaction between the GPCR and signaling molecules, especially whether the interaction is the cause or the result of activation of the signaling molecules, remains to be determined. Nonetheless, these receptor sequencespecific cell signals initiated by GPCR stimulation confer more versatility to the GPCRs.
Unsolved Questions and Future Directions
The AT 1 receptor signaling demonstrates diverse cell-type specificity. 32, 33 Li et al 20 reported an interesting observation that PKC activation normally suppresses the tyrosine kinase (EGFR)-Ras-ERK pathway. However, once PKC is inactivated, this tyrosine kinase-dependent pathway completely compensates for ERK activation in liver GN4 cells. 20 If this observation is applicable to other cell types, the PKC dependence of ERK activation would be determined by the strength of the tyrosine kinase activities of the given cell types.
Another important issue is the unique Ang II-dependent cell signaling among G q agonists. In cardiac myocytes, many Gq-agonists, including Ang II, phenylephrine, and endothelin-1, are known to induce cardiac hypertrophy. 34 These agonists seem to activate a similar set of signaling molecules. However, the profile of the signaling molecules activated by hypertrophic agonists has not been elucidated in detail. A recent report suggests that phenylephrine activates p38, resulting in an impressive hypertrophic response in cardiac myocytes. 35 It would be interesting to compare activation of p38 among hypertrophic agonists. If these receptors use sequence-specific signaling mechanisms as described above, sequence comparison among GPCRs would provide pertinent information.
Recent progress in the Ang II signaling field has made the linkage between AT 1 receptor and tyrosine kinase more clear and more significant compared with that a few years ago. We now understand in part why Ang II activates an array of signaling molecules as well as how Ang II can stimulate cell growth responses of the cardiovascular system almost as potently as agonists for the receptor-type tyrosine kinases do in other cell types. However, the mechanisms of many events proximal to the AT 1 receptor, such as tyrosine kinase activation, possible G protein-independent signaling mechanisms, and small GTP binding protein activation, remain unclear. Further investigation, including the structure-function analysis of the AT 1 receptor and identification of the receptorassociating protein, will be required to address such questions.
